EMG
RARE icon

Ellington Management Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ellington Management Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,000
Closed -$416K – 735
2019
Q1 		$416K Buy
+6,000
New +$343K 0.08% 275
2018
Q4 		– Sell
-3,100
Closed -$237K – 572
2018
Q3 		$237K Buy
+3,100
New +$252K 0.06% 396

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ellington Management Group's RARE Position: Q2 2019 in Review

Ellington Management Group sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2019, closing a stake of 6,000 shares — an estimated $416K sold.

Ellington Management Group first reported a position in RARE in Q3 2018 and held it in 2 quarters. The position peaked at $416K in Q1 2019. 170 funds tracked by Wall St. Rank hold RARE as of Q2 2019.

  • Ellington Management Group reported no remaining Ultragenyx Pharmaceutical position as of Q2 2019 after selling out during the quarter.
  • Ellington Management Group sold 6,000 Ultragenyx Pharmaceutical shares in Q2 2019, an estimated $416K.
  • Ellington Management Group first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and held it in 2 quarters.
  • Ellington Management Group's Ultragenyx Pharmaceutical position peaked at $416K in Q1 2019.
  • 170 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2019.

Based on Ellington Management Group's 13F filing for Q2 2019, filed 14 Aug 2019.